Dupilumab (CAT: I017509) is a monoclonal antibody used for the treatment of certain inflammatory conditions, specifically moderate-to-severe atopic dermatitis (eczema) and moderate-to-severe asthma. It works by targeting and inhibiting the interleukin-4 receptor alpha (IL-4Rα), which plays a key role in the immune system’s response to allergic and autoimmune diseases. By blocking IL-4Rα, dupilumab helps reduce inflammation and associated symptoms in patients with atopic dermatitis and asthma. It has demonstrated efficacy in improving skin lesions and reducing the need for topical corticosteroids in eczema patients.
| Catalog Number | I017509 |
| CAS Number | 1190264-60-8 |
| Purity | ≥95% |
| Reference | [1]. Hamilton JD, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300. |
